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Objectives: To examine substance abuse treatment providers’ views on engaging clients in Pre-exposure Prophylaxis
(PrEP) care and research trials.
Methods: Thirty-six medical and counseling service providers in six New York City outpatient substance abuse
treatment programs participated in semi-structured qualitative interviews. Thematic content analysis was conducted
by three coders, independently.
Results: Providers’ perspectives toward PrEP were characterized by six salient themes: 1) Limited PrEP awareness.
2) Ambivalence about PrEP; 3) Perception of multiple challenges to delivery; 4) Uncertainty about clients’ ability to
be adherent to medication; 5) Concerns about medication safety/side effects; and 6) Perception of multiple barriers
to conducting clinical trials.
Conclusions: Despite anticipated challenges, providers supported the introduction of PrEP in outpatient substance
abuse treatment. Comprehensive training for providers is needed and should include PrEP eligibility criteria, strategies
to support adherence and medication monitoring guidelines. Linkages between substance abuse treatment and
primary care and/or enhancement of capacity within clinics to offer PrEP may help facilitate PrEP delivery. When
conducting research in outpatient clinics, it is particularly important to protect client confidentiality.
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treatmentIntroduction
In the US, there are approximately two million substance
users in community treatment programs who are at risk
for HIV [1]. Because of injection drug use (IDU) and/or
unprotected sex under the influence of drugs and/or
alcohol, substance users, and their sexual partners, are
vulnerable to acquiring HIV. Sexual transmission accounts
for the greatest proportion of new HIV infections [2]. The
association between sexual risk and substance abuse is
well documented among opposite-sex, as well as same-sex
partners ([3-5]).
Studies of New York City substance users in (D.C. [6])
and out of (D.C. [7,8]) treatment for substance abuse
show that injection drug users (IDUs) and non-IDUs
have nearly the same prevalence of HIV due to the
strong connection between sexual risk and substance* Correspondence: ay2117@columbia.edu
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unless otherwise stated.abuse [9]. In particular, stimulants, especially cocaine
[10], methamphetamine [11-13], “club drugs” [14] and
alcohol ([15-17]) have been shown to be drivers of sex-
ual risk behavior. Sometimes, this is in the context of
“survival sex” or exchange of sex for money and/or
drugs, which is also strongly associated with HIV risk
([18,19]). Sex work, while criminalized and punishable
by arrest and sometimes imprisonment, is common in
New York City. While HIV infection among IDUs has
markedly declined due to syringe exchange programs
[20-22], IDU is still an important risk factor.
The interrelationship between HIV and substance abuse
necessitates a coordinated effort for providers (e.g., coun-
selors, nurses, physicians) of substance abuse treatment
[23] to prevent HIV among this vulnerable population.
There are several evidence-based HIV prevention inter-
ventions available, however they are often not integrated
into substance abuse treatment practices. In HIV preven-
tion, the gap between research and practice is known tol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been shown to be efficacious in preventing HIV acqui-
sition among individuals at risk for HIV infection, if they
are adherent to its use [25], and it has recently been
approved by the FDA. Thus far, PrEP initiatives have been
focused on men who have sex with men (MSM) and HIV
seronegative partners in serodiscordant couples [26]. As
PrEP rolls out, it would be timely to conduct research to
determine the feasibility, acceptability, and impact of PrEP
on providers’ practices, in substance abuse treatment
community programs.
While primary care providers in community clinics
have expressed willingness to prescribe PrEP to patients
that are at risk for HIV, they sometimes do not agree on
how to determine PrEP eligibility. Likewise, they noted
implementation challenges including: difficulties moni-
toring PrEP within the current primary care structure,
managing adherence issues and side effects [27]. Physi-
cians specializing in HIV primary care were more aware
than generalists about PrEP efficacy and safety, yet most
physicians expressed some concerns about prescribing
guidelines and monetary costs for PrEP [28]. No study
thus far has examined providers in non-primary care
settings’ perspectives on PrEP, despite the likelihood that
they too may be called upon to recommend PrEP to
their patients/clients.
Substance abuse treatment providers are fundamental
to the adoption and delivery of PrEP, and the implementa-
tion of PrEP research, through their roles in counseling
and coordination of care with clients’ primary care pro-
viders. Yet, the personal and organizational motives and
challenges that providers can anticipate – in delivering
PrEP and participating in PrEP research – are not known.
Such information is crucial to developing PrEP programs
in substance abuse treatment – that offer the greatest
promise for integrating PrEP, or linkage to PrEP, within
substance abuse treatment. Such information is also
crucial to identifying potential approaches to engage
substance users in PrEP, and monitor and support their
adherence.
To fill these important gaps, we conducted a qualitative
study of outpatient substance abuse treatment providers’
perspectives toward providing PrEP in their programs.
This leveraged the existing platform of the Greater
New York Node of the NIDA Clinical Trials Network
(CTN) – a network of community-based treatment and
medical care facilities dedicated to carrying out effective-
ness trials of proven (pharmacologic and/or behavioral)
interventions for substance users. Outpatient substance
abuse treatment programs in New York City include
psychosocial programs, methadone maintenance pro-
grams, and harm reduction programs that offer syringe
exchange. In this study we included four programs that
offer psychosocial treatment and two programs thatoffer both psychosocial and methadone maintenance.
Three programs were hospital-based and three were
community-based. In each of six programs, a comple-
ment of providers – including counselors, physician
and Director – was recruited. Each provider participated
in a semi-structured interview – which elicited his/her
views of important issues for PrEP program and research
implementation. In doing so, this study aimed to obtain
critical information for the integration of PrEP into treat-
ment. In particular, we aimed to: 1) inform best practices
for implementing PrEP research in substance abuse treat-
ment; 2) suggest strategies to optimize delivery of PrEP;
and 3) identify needs for provider training and potential
salient targets for training.
Methods
Recruitment
Eligible agencies offered: 1) outpatient substance abuse
treatment services in New York City and 2) were in the
Clinical Trials Network (CTN). Twelve agencies were
eligible. Seven executive directors (EDs) were success-
fully contacted by the PI, first by introductory email, and
then with a follow-up phone call. The PI explained the
purpose of the study, inclusion criteria, and incentives.
Further, inclusion criteria for participants required that
six providers (one clinic director, one medical provider
and four counselors) from each agency be interviewed.
Each interviewee would receive a $40 cash incentive. Six
EDs agreed to participate in the study. One ED declined
to participate due to restructuring at the hospital where
the program was based. All human subjects procedures
were approved by the appropriate Institutional Review
Board.
Interview procedures
Using a community based participatory research approach
(CBPR), which has been shown over the past two decades
to enhance the external validity and relevance of research
findings [29], the semi structured qualitative interview
protocol was developed collaboratively over a series of
discussions by the study’s PI (an experienced provider of
both substance abuse and HIV services) and two commu-
nity based collaborators: one with expertise in substance
abuse treatment and one with expertise in HIV preven-
tion. Interview development followed an iterative process
to reflect the context of outpatient substance abuse
treatment and the professional language commonly
used in treatment settings so as to maintain a culturally
appropriate stance.
The PI conducted interviews at each site in a private
office space provided. The clinic director at each site
scheduled interviews in advance so as not to disturb
the workflow in the clinic and minimize burden on the
clinic staff. Interviews lasted approximately 30 minutes
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names or any other identifying information were recorded.
At the start of the interview, participants received a study
information sheet, as well as a packet of information sum-
marizing the “state of the art” evidence-based behavioral
and bio-behavioral HIV prevention strategies and PrEP.
Participants were guided through the information and
were encouraged to ask questions about PrEP and to
reflect upon what they had learned. Through open-ended
questions, providers were asked to describe their reactions
to PrEP, how they might anticipate implementing PrEP at
their clinics and to what extent they would be receptive to
conducting PrEP trials at their clinics. They were asked to
describe barriers and promoters to these PrEP initiatives.
Sample characteristics
36 Providers (N = 36) were surveyed from 6 outpatient
substance abuse treatment clinics (three hospital based and
three community based). Two of the three hospital based
programs and one of the Community based programs
offered Methadone Maintenance. Eight providers were
medical, six were clinic directors, and 22 were counselors.
The providers at the agencies held the following licenses/
degrees: 10 held Masters of Social Work degrees, 5 held
both Masters of Social Work degrees and Credentialed
Alcohol and Substance Abuse Counselor (CASAC) desig-
nation, 1 had a Master of Social Work and a Master of
Exercise Physiology degree, 2 held Bachelor’s degrees and
CASAC, 2 held Bachelor’s degrees, 6 providers held only
CASAC, one provider was a Licensed Practical Nurse, 1
provider was Registered Nurse, 1 provider was a Nurse
Practitioner, 1 provider was a Physician Assistant, 5 pro-
viders were Medical Doctors, 1 provider held a Master of
Science in Vocational Counseling.
Qualitative analysis
Data analysis was conducted by the PI and the two com-
munity consultants, over a series of in person meetings,
based on a modified Grounded Theory approach using
thematic content analysis [30] and organized through
ResearchWare HyperResearch qualitative data manage-
ment software. Themes, and their variations, focused on
providers’: (1) awareness of, and experiences with PrEP;
(2) barriers and promoters associated with use of PrEP
or with conduct of PrEP research with substance using
clients (3) strategies for negotiating perceived challenges
to participating in these initiatives.
The panel of three coders independently coded the first
two interviews using a line-by-line open-coding strategy
according to thematic content analysis to identify chunks
of text that fall under the themes of inquiry, PrEP: 1)
awareness/experiences; 2) barriers/promoters, and 3)
strategies to overcome challenges and 4) providers’
perspectives, opinions, and practices related to PrEP.Meetings to compare coding and to achieve 100% con-
sensus were held in order to build a codebook.
Subsequently coders coded the next two interviews and
met to discuss and compare, adding additional domains
as they emerged and meeting regularly until saturation
occurred. Saturation of data occurred after twelve inter-
views. The codebook was finalized at this point. We
then analyzed all transcripts based upon the codebook,
which contained definitions of each domain. These def-
initions were used to mark the text of all transcripts.
We marked only text that matched the definitions in the
codebook. Once we determined which passages in the
transcripts best represent the constructs in the codebook,
a grid containing these passages was created. These
passages (“quotes”) were then reviewed, and revised for
grammatical clarity and entered into HyperResearch
qualitative data management software.
Reports were extracted based upon the findings that
emerged related to PrEP and organized according to
content analysis. This resulted in the analysis of salient
themes. Based upon the themes of inquiry, six areas
emerged as most salient for the providers. These are: 1)
Limited awareness of PrEP. 2) Ambivalent perspectives
toward offering PrEP. 3) Challenges in delivering PrEP. 4)
Uncertainty about adherence to PrEP. 5) Concerns about
safety/side effects. 6) Barriers to conducting clinical trials.
Results
Findings are presented across job roles, organizations,
and educational backgrounds.
Limited awareness of PrEP
There was an overall lack of awareness of PrEP in this
sample, with only four of the 36 providers having had
prior awareness of PrEP. One was a hospital administra-
tor, a psychiatrist, who has had extensive involvement in
clinical and behavioral research trials as a site co-PI with
academic partners; one who was a psychiatrist who had
recently completed a post-graduate research fellowship
in addiction; one was a nurse practitioner who recently
graduated with a Masters in nursing; and one was an
MSW-level social worker who had recently completed
graduated school. The remaining 32 providers said they
had never heard of PrEP or were not aware that there
were pharmacological approaches to HIV prevention.
For 32 of the providers surveyed, the informational
materials provided by the PI were the first instance they
were learning of PrEP.
Ambivalent perspectives toward offering PrEP
The four providers that already knew about PrEP felt
favorably toward offering PrEP to their clients, stating that
it would be beneficial to substance using clients, particularly
because of sexual, and in some cases, needle-sharing risk.
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studies” describing PrEP trials, however he was unaware
that PrEP had since received FDA approval. Therefore,
while this provider was aware of PrEP, the lack of awareness
of PrEP’s availability would have prevented the provider
from presenting this as an option to an at-risk client.
“Yes. I’ve heard about – research related to it. That you
take high-risk people, like injection drug users, or people
with high risk sexual behavior, and prophylactically give
them antiretrovirals. And – and my understanding of
the research is that it’s highly effective in preventing, you
know, similar to – similar to giving antiretrovirals to
mothers who were pregnant, you know, seriously reduced
the risk of kids getting it” (M.D., hospital-based).
For those providers who had not heard of PrEP, initial
reactions to learning about PrEP were overwhelmingly
positive. 29 providers stated that PrEP was a welcome
advance in prevention and that it would be a benefit to
their clients. All of the medical providers had a strongly
positive reaction to PrEP and stated their support for
offering PrEP to their clients. Counseling providers in
general reacted favorably and considered PrEP as a tool
that could be used as a complement to counseling.
“I think if they’re already engaging in risky behaviors,
I think it’s safe to be safer, and to have something in
place, and not to just tell them not to do the risky
behavior. You could work on the risky behaviors while
they’re taking the pill and being safe at the same time.
So then we could discuss how to discontinue risky
behaviors but in the meantime you’re safe until they
get to that point so I think that’s excellent.”
(Counselor, community based).
Four providers reacted negatively and 2 were neutral,
mainly due to a belief in “risk compensation,” the notion
that PrEP would result in a client feeling protected against
HIV and therefore more likely to engage in risky sexual
behavior [31]. These six providers (all counselors) believed
in risk compensation and characterized PrEP as a “permis-
sion slip” to act out sexually. They suggested that PrEP
would lead clients to engage in unprotected sex “reck-
lessly” and objected to its use on this basis. They used a
moral argument with regard to this medication stating
that they had moral objections to offering it to clients.
“I already know that everything is not for everybody,
because we have some people that have very
promiscuous behaviors. And I think a drug like this
would probably or could – has the potential to make
them, like I said, more promiscuous.” (Counselor,
community based).Challenges in delivering PrEP
Providers had never implemented PrEP in their clinics, nor
had they participated in PrEP research trials. Providers’
were asked about their anticipated practices for delivering
PrEP in their outpatient substance abuse treatment setting.
In other words, how they anticipate the process of imple-
mentation may look or how they suppose barriers to
implementation may present.
Providers anticipated the following challenges regarding
offering PrEP: 1) Educating clients through counseling
about PrEP, when they themselves had very little/limited
information about PrEP, 2) Prescribing and/or monitoring
PrEP without qualified medical staff to prescribe (e.g.,
psychiatrists or physicians) and without sufficient funding
for medication monitoring through blood tests, 3) deter-
mining eligibility criteria (i.e., how to identify which clients
should receive PrEP), 4) making referrals to (primary care)
providers who can prescribe PrEP without referral-making
procedures and policies in place.
Nearly all of the counseling and some medical providers
stated that their PrEP implementation would consist
mainly of offering education and information to clients
about PrEP as an option for HIV prevention. They were
willing to discuss PrEP, hand out written materials, and
offer general information about the availability of PrEP.
“Right. Yeah. I would empower them, you know, with
having, you know, that as a choice, you know, an
option, you know, in their life, you know, it’s the same
way I would – might tell them, you know, about other
programs and resources that are out there.”
(Counselor, community based).
However, in order to do so providers stated that they
would need training about PrEP and how to present the
information to clients.
“Yeah, serious training. Just, basically, what to say, how
to say it, and really something that we will remember as
far as our own interpreting it into our own words and
giving it to the client.”-counselor, community based.
Despite willingness to offer information, only 7 said
that they would make a referral for a client to obtain
PrEP at a primary care clinic or in the case of hospital
based programs that offered primary care, at primary
care onsite services.
“I think I would, you know, I would educate them about
it. You know, I wouldn’t necessarily– maybe I wouldn’t
go ahead and make a direct referral to them….but I
would raise it, you know, raise it to the client’s attention,
you know, that it’s something, you know, that’s available,
you know” (Counselor, community based).
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would educate them that it’s out there, and that’s it.”
(Counselor, hospital based).“Yeah, we have to offer the alternatives. Now, I’m not
endorsing it. That’s the caveat. I’m not endorsing it,
but these are your options. This is what’s out there,
you know, and please speak to your physician.”
(Counselor, hospital based).
A few medical providers were inclined to make referrals
and to help the client obtain PrEP. Being situated in a
hospital setting seemed to encourage referral making,
especially for primary care and HIV antibody testing
because of the natural link between the substance abuse
program and the larger health care system.
“Well, we’re lucky, in a sense, that we can – we do have,
like, a very, very strong sort of medically-based presence
here in this treatment program. Many programs do not
have that luxury. But then, we also are, you know, in a
hospital. We can have a relationship with the virology
clinic”-(Medical provider, hospital based).
The program directors shared the following concerns:
1) that they did not have prescribers and/or sufficient staff
available, 2) did not have the capacity to monitor PrEP
adherence, and 3) were unsure about how PrEP would be
covered in terms of third-party reimbursement.
“I think what you’re going to hear from many of the
staff is that they feel like it’s just one more thing on my
plate. They feel like they have so much work to do
because, as I mentioned,– our staffing has gone down
but the amount of work that we do has stayed the
same. So you basically have fewer people doing
more work. You know, at least in our clinic, in our
setting – and I know other settings have been different,
but we’d never had productivity requirements. Now all
the providers have productivity requirements.”
(Program Director, hospital based).
Two program directors reported that their staff would
need comprehensive training on PrEP in order to be able
to educate clients. Further, one program director noted
that staff needed training in psychopharmacology in gen-
eral because many clients are dually-diagnosed with mental
health conditions and require counseling around medica-
tion adherence for other disorders and conditions.
“So, I think that that would depend – they would
require a lot of education, because I think our staff, in
general… Well, I would say the younger staff is more
open, and they have more education. We do have someolder staff who have been in the field for a long time,
maybe don’t have as much education, and tend to shy
away from medications, in general. So, even to get
them to understand, like, a co-occurring disorder, and
a client would benefit from taking a psychotropic
medication of some sort along with their treatment
regimen – is a good thing. It – that requires a lot of
education.” (Program Director, community based).
Overall providers’ criteria for clients to receive PrEP was
two-fold: exhibiting a demonstrated risk either through
exchange sex, unprotected sex with multiple partners, or
needle sharing; and exhibiting psychosocial stability dem-
onstrated by stable housing, program attendance, sobriety,
medication compliance and overall medical health. When
asked what types of clients would be good candidates for
PrEP, 22 providers said that the client’s level of risk should
guide the assessment of whether they are offered PrEP.
“So if you look at something like that and you take an
assessment of how – what risk level they’re at, then I
would suggest absolutely, why not put the medication
in there. But I think there should be a – there should
definitely be a risk level and – yeah.” (Counselor, com-
munity based).
When asked to elaborate they used the following terms
to describe such clients: “high risk”, “risky behaviors”,
“don’t want to use condoms” or “multiple partners” and
“promiscuous” to describe the ideal candidate for PrEP.
Two providers stated that PrEP would be ideal for “prosti-
tutes” and three mentioned IDUs.
“OK, well, a client that – let’s say a client that has
reported a sex addiction, and has multiple partners,
doesn’t wear a condom, things of that nature. Clients
such as that I would probably recommend that to.”
(Counselor community based).“Or just, you know, like I said, people who are high
risk because maybe they are promiscuous or maybe
they are interested in, you know, using prostitutes or
because they are still sharing needles” (Counselor,
hospital based).
Eight providers stated that PrEP would be ideal for
serodiscordant couples and one counselor described
PrEP as a way for his HIV positive client to have “normal
marital relations”. Providers appeared most comfortable
and approving when discussing using PrEP for serodiscor-
dant couples. One provider explicitly stated that that
takes the “moral question” out of it. Two providers
mentioned young age as a criterion, stating that they
felt that younger clients (under age 30) are most at risk
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being generally more sexually active, whereas the older
clients were engaged in stable and presumably monog-
amous partnerships.
“You know, young people who are sleeping around – I
mean, you know, that would be a great thing to take.
You could prevent it – if you can’t convince them to
wear a condom, you could take this.” (Psychiatrist,
hospital based).
Four providers stated that being “stable” medically and
having achieved a minimum length of time (between three
and six months) of abstinence from drugs were requisites,
as well as being compliant with their other medication
regimens (e.g., psychotropic medications). One provider
mentioned stable housing as a requirement. One director
of a program mentioned that regular attendance and not
missing appointments were important criteria.
“it’s counterintuitive, because the client who’s going to
be a client that would benefit from this is likely to be a
client who would be least likely to comply with all the
stipulations that would be associated with it…Yeah,
the two things would go hand in hand, because the
person who’s running around having a lot of risky
behaviors is generally not a person who’s going to a
primary-care doctor, and not a person… You
know”- Program Director, community based.“If you know your patient has history of multiple
partners, and a history of being homeless, and a
history of selling her body, and a history of constantly
using drugs, then you may be hesitant on giving this
patient this pill. You know what I mean? But, you may
say here, you need it. So you’ve got to weigh your pros
and cons, and every patient’s different. Their social –
you know, their social skills, their living situation,
everything you’ve got to take into account”.- medical
provider, hospital based.
Uncertainty about adherence to PrEP
Seventeen providers comprised of both counselors and
medical providers, reported that adherence would be a
serious concern for their clients. They stated that their
clients’ continued drug use, unstable housing, or simply
forgetting to take the medication may impinge upon
clients’ ultimate ability to maintain compliance of daily
dosing. Uncertainty about adherence gave some providers
pause when considering whether they would recommend
PrEP, particularly in light of the potential consequences
of skipping doses (e.g., developing resistance). One
psychiatrist asked, “How long does it last?” in an effort
to establish the length of time that a client wouldexperience a prophylactic effect even if they were to
miss a dose.
Most of the medical staff reported that they were
concerned about non-compliance with this population.
“They would definitely need to be monitored, I’m sure.
With these kind of clients they need consistency. So
they’re not going to do it on their own. They’re not going
to remember.”- (Medical provider, community based).
Five non-medical providers reported that adherence
would not be a concern and that their clients would
indeed be able to comply with medication, particularly
because many clients already take medication for med-
ical or mental health conditions.
“..you have outpatient, then you have the methadone
clients. Those guys I don’t think would have a problem
[with adherence]. – (Counselor, hospital based).
Concerns about PrEP safety/side effects
The majority of providers relayed concerns about long-
term effects of PrEP and safety for clients that have
co-morbid medical issues (e.g., hepatitis C) some asked
about how PrEP may interact with other medications
that clients were taking (e.g., methadone). One provider
asked about PrEP’s safety during pregnancy, and one
provider asked about whether PrEP had been tested with
adolescents. Most providers, both medical and non-
medical, were reluctant to offer or recommend PrEP
to clients that were already ill with chronic conditions
because of concerns about liver toxicity.
“Right. OK. Yeah. I think definitely, because you want
to find out in the event that, you know, is it safe to
take with methadol. Is it take to – take with suboxone,
is it safe to, actually, take with any other medications
they may be taking for their medical issues.”-
(Counselor, hospital based).
Concerns over side effects were less prevalent than
safety concerns, although one provider pointed out that if
the client experiences side effects he/she may discontinue
the medication therefore it is important to consider the
severity of the potential side effects.
Barriers to conducting clinical trials
Most providers agreed that participating in a trial of
PrEP would be a benefit to their clients because they
would be able to secure access to the medication for no
cost. Nearly all of the providers stated that they would
be willing to be involved with a PrEP trial in terms of
conducting study tasks and procedures (e.g., recruitment,
data collection).
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consent. Providers affirmed necessity of clients under-
standing the risks and benefits prior to engaging in PrEP
research. They stated that clients would need to be well
counseled around drug safety and potential side effects,
particularly because many clients have a low education
level and may be compromised cognitively due to drug
use. 2) Maintaining confidentiality. Seven providers were
concerned about securing confidentiality in offering PrEP
on site through clinical trials. They were hesitant to
engage clients in trials if there was a risk of clients being
stigmatized by peers or staff due to being perceived as
“at risk” or as part of a serodiscordant couple. Moreover,
concerns about maintaining the confidentiality of clients’
partners or significant others arose because peers may
conclude HIV status of partners if the client is enrolled in
a PrEP trial.
“But will people will come saying, you know, I have a
partner or I have, you know. And then, at that point,
does the HIV status of the partner become identified?
Hopefully not. That’s not what we’re interested in.
We’re interested in protecting the patient.”- (Medical
provider, hospital based).
3) Mistrust toward research. Five counseling providers
mentioned mistrust toward research as a potential barrier
to engaging clients in PrEP trials. Clients may be reluctant
to take PrEP and/or enroll in trials for fear of being
treated as “guinea pigs”.
“I don’t know. I think people like, just medication in
general, they think of the side effects, they think of
testing as being used as guinea pigs, as research work
as guinea pigs, and what if there is something along
the way that comes up?”- (Counselor, community
based).
Providers related this perception to historical abuses of
vulnerable populations and people of color in general by
the scientific community, as well as to conspiracy theory
beliefs about HIV.
4) Role of incentives in recruitment. Six providers
advocated monetary incentives as the most important
strategy that may help overcome barriers to enrolling
clients in PrEP trials.
If the incentives were good, definitely a lot of people are
open to research trials. – (Counselor, community based).
Limitations
One limitation of our study was the selective nature of
the sample as being nominated by the program directors
for the interviews. However, despite being hand-selected
by the administrators, the providers interviewed werenot exceptionally knowledgeable about HIV, nor particu-
larly experienced with HIV prevention. Therefore, we
believe that the providers interviewed are adequate
representatives of their respective organizations. Thus,
the same themes and issues emerged across clinic and
across job role from our data suggesting that this popu-
lation has many common concerns and practices. The
main limitation was that the clinics in this study might
not represent all substance use treatment programs in
the U.S. or in New York. The clinics we interviewed are
relatively well resourced and participate in the Clinical
Trials Network (CTN), therefore may be more receptive
to research than non-CTN affiliated clinics.
Discussion
To our knowledge, this is the first study to explore sub-
stance abuse treatment providers’ views on PrEP. Given
the HIV risk faced by many substance-using clients, it is
crucial to assess the potential for implementation of
PrEP within substance abuse treatment settings and to
understand the perspectives, barriers and promoters
from the standpoint of the providers that will ultimately
be responsible for PrEP’s uptake in these settings. A few
major themes emerged from our study of medical staff,
counseling providers and directors. These findings cut
across the various job roles and clinic settings.
Only a small proportion of our sample (approximately
10%) had ever heard of PrEP prior to the interview. This
was surprising, given the fact that the clinics are located
in New York City, the epicenter of the HIV epidemic
and boasting cutting-edge HIV research and services.
The overwhelmingly positive response of most providers
upon first learning of PrEP was encouraging given the
controversy surrounding PrEP, and suggests that this
work force is open to innovation and to using pharma-
cological interventions. This is not surprising given the
fact that many work with clients that are prescribed
psychotropic medications and opiate-substitution regi-
mens. The providers who voiced objections to PrEP did
so mostly on the basis of risk compensation, which is an
argument that has, in the past, been used to argue against
oral contraception, condoms, etc. Risk compensation has
been shown in some populations (e.g., men who have sex
with men) with regard to inconsistent condom use leading
to riskier sex with multiple casual partners, however, there
is yet to be any empirical support for risk compensation
among those receiving PrEP [32].
Behavioral counseling has been recommended as a
strategy to use in concert with pharmacological interven-
tions like PrEP in order to increase clients’ risk perception
and to mitigate the potential consequences of risk com-
pensation [33]. Thus counseling providers may play a
crucial role in reducing risk compensation if this effect is
indeed found among PrEP recipients. Despite not having
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PrEP and agreed that PrEP could be beneficial to their
clients. Therefore, opportunities exist to enhance pro-
viders’ understanding of PrEP by targeted education.
Future research may seek to identify dissemination
channels that are aligned with providers’ preferences to
circumvent barriers to training such as lack of time or
funding.
Providers perceived their roles in PrEP implementation
in different ways. Because our sample consisted mostly of
counselors (78%) that do not prescribe medication it is
not surprising that counselors considered their primary
role to offer clients PrEP “information and education”.
However, even medical providers in our sample that could
prescribe PrEP, declined to do so because their roles in the
clinics were not to provide primary care but rather, psy-
chiatric care (e.g., antidepressants) or care related directly
to substance use (e.g., buprenorphine, methadone). Nearly
all providers, medical and counseling, were willing to offer
information or education to clients (e.g., pamphlets).
While this is an important initial step toward engaging cli-
ents in PrEP, it is equally important to help clients gain ac-
cess to PrEP through formal referrals to obtain the
medication, and only 20% of our sample including medical
and non-medical providers, stated that they would be will-
ing to offer referrals for obtaining PrEP. While most pro-
viders stated that they felt PrEP would be a benefit to their
clients, their lack of willingness to make referrals indicates
ambivalence toward PrEP and/or perhaps, toward making
referrals. Future research needs to develop and test
strategies to overcome barriers to referral making among
providers of substance abuse services. Likewise, develop-
ing strategies to foster linkages between substance abuse
treatment medical staff, counseling staff, and primary care
services may help to facilitate referrals for PrEP.
The program directors’ concerns about implementation
were related to three programmatic issues: 1) lack of med-
ical staff to prescribe and monitor PrEP, 2) cost of PrEP
and third party reimbursement (i.e., Medicaid), and 3)
securing training for providers on how to educate clients
about PrEP. Policymakers interested in the roll-out of
PrEP within community based organizations including
substance use treatment programs need approaches that
take into account issues of cost, capacity and resource
allocation so that PrEP treatment can be sustained and
managed within these settings. Since most clients
receiving treatment services in the locations surveyed
are Medicaid recipients, it is important to advocate for
Medicaid’s continued coverage of PrEP. Likewise, policy-
makers may include outcome measures on PrEP uptake
for the purposes of reporting program-level data to fun-
ders and licensing agencies in order to motivate the use of
PrEP as well as develop buy-in among implementers at
the program level.Most providers deemed clients that engage in “high
risk” sexual behavior (e.g., unprotected sex, multiple
partners), sex workers, clients that inject drugs, and ser-
odiscordant couples as potential candidates for PrEP.
However, they also considered stability in housing, mental
health, abstinence from illicit drug use, and medical well-
ness as important criteria. Thus, the very same individuals
that are most in need of PrEP according to providers may
not be eligible for PrEP based upon the aforementioned
criteria. The conflict inherent in targeting PrEP to those
that are most chaotic and at-risk while limiting eligibility
to individuals that are most stable points to an area of
confusion. Providers need guidelines for identifying appro-
priate substance using clients in community settings so
that they may conduct initial screening for PrEP prior to
initiating a referral and/or offering to prescribe PrEP.
Relatedly, most providers were concerned about adher-
ence to a daily medication for this population in particular
and had doubts about clients’ ability to comply with dos-
ing due to forgetting, relapsing with drugs/alcohol, or due
to a history of non-compliance with other medications.
Currently in development, long-acting injectable PrEP
has been shown to be effective in monkeys and will soon
be tested in humans [34]. Future research investigating
other forms of PrEP for substance users such as long-
acting injectables and vaginal rings may help minimize
adherence concerns. Developing methods of delivery other
than daily oral dosing may avert issues of compliance,
maintaining abstinence from drugs, and reduce reliance on
access to resources like housing or food, which may impede
clients from taking oral PrEP. Therefore, alternative forms
of PrEP may be most responsive to the lived experiences
and real-world challenges experienced by substance users.
In the meantime adherence interventions may be used to
foster compliance with medication regimens [35].
Most pronounced were providers’ concerns about drug
safety and side effects, particularly in light of the medic-
ally compromised clients that are already infected with
HCV. Long-term effects of taking antiretrovirals were
also noted and providers wanted to know whether it was
known how clients’ livers and other organs would be
affected over time. Based upon the providers’ focus on this
area of concern, we hypothesize that any ambivalence
toward PrEP was rooted in being unconvinced of PrEP’s
safety and a fear of harming their clients. Thus, training
for providers targeting these issues may help to overcome
potential barriers to referring clients for PrEP.
However, it is worth noting that concerns about confi-
dentiality raise the issue of PrEP stigma and HIV stigma
with this population. The concern that clients might
identify peers as PrEP recipients, should PrEP trials be
conducted on site, and that this may result in stigma-
tization, points to a need to protect clients’ confidentialities,
while at the same time working to educate the substance
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to dispel myths about HIV transmission, reduce homopho-
bia, and assumptions about what constitutes risk.
Providers’ overwhelming support of conducting PrEP
research trials on site and engaging their clients in trials
may be an artifact of the sampling frame being CTN-
affiliated programs. All of the programs are currently, or
have in the past participated in clinical, behavioral and in
many cases, pharmacological research through the CTN.
Therefore, these programs in particular have a positive
orientation toward research collaboration so this may not
represent all substance use treatment programs in New
York City or in the United States. This study suggests that
more research ought to be done prior to rolling out PrEP
in substance abuse treatment programs. PrEP research
should focus on testing implementation strategies include
structural interventions in order to build agency capacity
to sustain PrEP. Interventions aimed at enhancing link-
ages to PrEP prescribers ought to be leveraged for those
programs that lack the capacity to do so.
Conclusion
The workforce of substance abuse treatment providers is
poised to engage their at-risk clients in PrEP through
counseling, referrals, research trials, and may promote
sustained use of PrEP by helping clients to maintain
adherence to medication regimens through counseling
and monitoring. Policymakers and funders will play a
critical roll in establishing the structural supports for these
initiatives. Structural supports may include trainings for
providers in a variety of HIV prevention strategies includ-
ing PrEP. Trainings may be delivered in-person, through
webinars, or through short films depending on budgetary
constraints and technological capacity. Likewise, clinics
that provide substance abuse treatment services may form
collaborative partnerships with primary care providers
that are equipped to prescribe PrEP. Such partnerships
may be cultivated through policy initiatives aimed at inte-
grating medical and behavioral services, a goal of the
Affordable Care Act [36]. This study helped to fill a gap
in the literature surrounding substance use treatment
providers’ perspectives toward the roll-out of PrEP as a
new tool for HIV prevention, their willingness to engage
their clients in PrEP research, and the challenges that they
anticipate to delivering PrEP to their population. Despite
many challenges including limited awareness, miscon-
ceptions about PrEP, concerns about safety, and lack of
capacity to prescribe and monitor PrEP, providers were
highly motivated to learn more through training, and
were deeply committed to helping their clients stay
healthy. Given access to training, supervision, and link-
ages to appropriate referral sources, substance abuse
treatment providers are likely to engage at-risk clients
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